Please provide your email address to receive an email when new articles are posted on . The regional treatment conferred a significantly higher overall response rate than best alternative care. Median ...
Sugemalimab Monotherapy for Patients With Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (GEMSTONE-201): Results From a Single-Arm, Multicenter, Phase II Study Supported by grants ...
An advanced surgical therapy has proved considerably more efficacious than conventional treatments for patients with melanoma in the eye (uveal) that has spread to the liver, a University of ...
STAMFORD, Conn.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq:DCTH) announces the expansion of the Company’s Phase II multi-histology clinical trial to include a fourth arm consisting of patients ...
An advanced surgical therapy has proved considerably more efficacious than conventional treatments for patients with melanoma in the eye (uveal) that has spread to the liver, a University of ...
Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication ...
Hepzato Kit, FDA-approved for metastatic uveal melanoma liver treatment, shows strong early revenue ($10M in Q3, $13.7M expected in Q4) with surprising profitability. The disease affects ~1,700 ...
Traditional liver perfusion procedures – used to isolate hepatocytes – are difficult to perform and require extensive training, steady hands and long-standing experience. In this webinar, a new, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results